237 related articles for article (PubMed ID: 18716777)
21. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas.
Bremer K
J Cancer Res Clin Oncol; 2002 Nov; 128(11):603-9. PubMed ID: 12458340
[TBL] [Abstract][Full Text] [Related]
22. Phase II trial of weekly paclitaxel and carboplatin chemotherapy in patients with advanced transitional cell cancer.
Johannsen M; Sachs M; Roigas J; Hinke A; Staack A; Loening SA; Schnorr D; Wille AH
Eur Urol; 2005 Aug; 48(2):246-51. PubMed ID: 15963636
[TBL] [Abstract][Full Text] [Related]
23. High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study.
Bengala C; Danesi R; Guarneri V; Pazzagli I; Donati S; Favre C; Fogli S; Biadi O; Innocenti F; Del Tacca M; Mariani M; Conte PF
Bone Marrow Transplant; 2003 Feb; 31(4):275-80. PubMed ID: 12621462
[TBL] [Abstract][Full Text] [Related]
24. Phase I/II trial of weekly epidoxorubicin and docetaxel (wED) in the neoadjuvant and palliative treatment of patients with breast cancer.
Wenzel C; Locker GJ; Pluschnig U; Zielinski CC; Rudas M; Oberhuber G; Gnant MF; Taucher S; Jakesz R; Steger GG
Cancer Chemother Pharmacol; 2002 Aug; 50(2):155-9. PubMed ID: 12172982
[TBL] [Abstract][Full Text] [Related]
25. Pathological and clinical response of a primary chemotherapy regimen combining vinorelbine, epirubicin, and paclitaxel as neoadjuvant treatment in patients with operable breast cancer.
Abrial C; Van Praagh I; Delva R; Leduc B; Fleury J; Gamelin E; Sillet-Bach I; Penault-Llorca F; Amat S; Chollet P
Oncologist; 2005 Apr; 10(4):242-9. PubMed ID: 15821244
[TBL] [Abstract][Full Text] [Related]
26. Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients.
Schmittel A; Knödler M; Hortig P; Schulze K; Thiel E; Keilholz U
Lung Cancer; 2007 Jan; 55(1):109-13. PubMed ID: 17097191
[TBL] [Abstract][Full Text] [Related]
27. [Relation of dose intensity and efficacy, toxicity in paclitaxel as a single agent for advanced breast cancer].
Liu F; Jiang ZF; Song ST; Liu XQ; Wang T; Yan M; Zhang SH; Hao CF; Sun JZ; Shen G
Zhonghua Zhong Liu Za Zhi; 2005 Jan; 27(1):56-8. PubMed ID: 15771802
[TBL] [Abstract][Full Text] [Related]
28. Dose-dense therapy with paclitaxel via weekly 1-hour infusion: preliminary experience in the treatment of metastatic breast cancer.
Seidman AD; Hudis CA; McCaffrey J; Tong W; Currie V; Moynahan ME; Theodoulou M; Tepler I; Gollub M; Norton L
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-72-S17-76. PubMed ID: 9374099
[TBL] [Abstract][Full Text] [Related]
29. A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer: sequential phase I/II studies.
Elias AD; Richardson P; Avigan D; Ibrahim J; Joyce R; McDermott D; Levine J; Warren D; McCauley M; Wheeler C; Frei E
Bone Marrow Transplant; 2001 Sep; 28(5):447-54. PubMed ID: 11593317
[TBL] [Abstract][Full Text] [Related]
30. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma.
Rummel MJ; Al-Batran SE; Kim SZ; Welslau M; Hecker R; Kofahl-Krause D; Josten KM; Dürk H; Rost A; Neise M; von Grünhagen U; Chow KU; Hansmann ML; Hoelzer D; Mitrou PS
J Clin Oncol; 2005 May; 23(15):3383-9. PubMed ID: 15908650
[TBL] [Abstract][Full Text] [Related]
31. Weekly paclitaxel in women with heavily pretreated metastatic breast cancer: a retrospective analysis of cases treated at the Chang Gung Memorial Hospital.
Lu CH; Lin YC; Chang HK
Chang Gung Med J; 2007; 30(1):33-40. PubMed ID: 17477027
[TBL] [Abstract][Full Text] [Related]
32. Doxorubicin-paclitaxel: a safe regimen in terms of cardiac toxicity in metastatic breast carcinoma patients. Results from a European Organization for Research and Treatment of Cancer multicenter trial.
Biganzoli L; Cufer T; Bruning P; Coleman RE; Duchateau L; Rapoport B; Nooij M; Delhaye F; Miles D; Sulkes A; Hamilton A; Piccart M
Cancer; 2003 Jan; 97(1):40-5. PubMed ID: 12491503
[TBL] [Abstract][Full Text] [Related]
33. [Weekly paclitaxel with concurrent intensity-modulated radiotherapy for nasopharyngeal carcinoma: outcomes of a tolerance trial].
Chen CY; Lu TX; Zhao C; Lu LX; Han F; Sun Y
Ai Zheng; 2007 Apr; 26(4):398-402. PubMed ID: 17430660
[TBL] [Abstract][Full Text] [Related]
34. Paclitaxel and epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil for patients with stage IIIC breast cancer with ten or more involved axillary lymph nodes.
Battelli N; Massacesi C; Braconi C; Pilone A; Manzione L; Dinota A; Cobelli S; Scanni A; Sturba F; Giacomini G; Morale D; Giorgi F; Tummarello D; Cascinu S
Am J Clin Oncol; 2006 Aug; 29(4):380-4. PubMed ID: 16891866
[TBL] [Abstract][Full Text] [Related]
35. Phase I clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumors.
Berkenblit A; Eder JP; Ryan DP; Seiden MV; Tatsuta N; Sherman ML; Dahl TA; Dezube BJ; Supko JG
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):584-90. PubMed ID: 17255281
[TBL] [Abstract][Full Text] [Related]
36. Weekly paclitaxel and 5-fluorouracil in pretreated patients with metastatic breast cancer: a phase I study.
Cortesi E; Grifalchi F; Ramponi S; Padovani A; Mancuso A; Paoluzzi L; Ferrau F; Oliva A
Anticancer Res; 2003; 23(2C):1961-6. PubMed ID: 12820487
[TBL] [Abstract][Full Text] [Related]
37. Increased dose density is feasible: a pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancer.
Fornier MN; Seidman AD; Lake D; D'Andrea G; Bromberg J; Robson M; Van Poznak C; Panageas KS; Atienza M; Norton L; Hudis C
Clin Cancer Res; 2007 Jan; 13(1):223-7. PubMed ID: 17200358
[TBL] [Abstract][Full Text] [Related]
38. Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization for Research and Treatment of Cancer Breast Cancer Group, Investigational Drug Branch for Breast Cancer and the New Drug Development Group Study.
Bottomley A; Biganzoli L; Cufer T; Coleman RE; Coens C; Efficace F; Calvert HA; Gamucci T; Twelves C; Fargeot P; Piccart M;
J Clin Oncol; 2004 Jul; 22(13):2576-86. PubMed ID: 15226325
[TBL] [Abstract][Full Text] [Related]
39. [A tolerability study of A cremophor-free albumin bound nanoparticle paclitaxel intravenously administered in patients with advanced solid tumor].
Teng XY; Guan ZZ; Yao ZW; Liu DG; Zhou NN; Luo HY; Hawkins M; Soon-Shiong P
Ai Zheng; 2004 Nov; 23(11 Suppl):1431-6. PubMed ID: 15566651
[TBL] [Abstract][Full Text] [Related]
40. [Clinical study of weekly paclitaxel administration for metastatic breast cancer based on time to progression (TTP) and survival].
Emoto T; Yoshikawa K; Yoshioka Y; Nezu R; Fujikawa M; Fujii M; Maeda S; Naka Y; Komaki T
Gan To Kagaku Ryoho; 2003 Jun; 30(6):817-22. PubMed ID: 12852349
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
